Mexico Gram Negative Infection Therapeutics Market Report 2023 to 2030

Mexico Gram-Negative Infection Therapeutics Market Analysis

$ 3999

The Mexico Gram-Negative Infection Therapeutics Market was valued at $223.1 Mn in 2023 and is predicted to grow at a CAGR of 6.15% from 2023 to 2030 to $338.8 Mn by 2030. This growth is driven by increasing prevalence, growing awareness, and rising investment in R&D. Major players in this market include Baxter and GlaxoSmithKline plc (GSK), among others.

ID: IN10MXPH563 CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico AUTHOR: Aryan Patel

Buy Now

Mexico Gram-Negative Infection Therapeutics Market Executive Summary

The Mexico Gram-Negative Infection Therapeutics Market was valued at $223.1 Mn in 2023 and is predicted to grow at a CAGR of 6.15% from 2023 to 2030 to $338.8 Mn by 2030.

Gram-negative bacteria are rod-shaped, non-motile, aerobic microorganisms that do not retain the crystal violet dye used in the gram staining procedure, appearing pink or red under a microscope. These bacteria can cause various diseases, including diarrhea, inflammatory bowel disease, typhoid fever, bubonic plague, cholera, and kidney damage. Important genera of gram-negative bacteria include Enterobacteriaceae, Vibrio, Campylobacter, and Pseudomonas. Treating infections caused by these bacteria often involves antibiotics such as ceftazidime/avibactam and cefiderocol, effective against Enterobacteriaceae and Pseudomonas aeruginosa with difficult-to-treat resistance profiles. These antibiotics are crucial for combating infections caused by gram-negative bacteria with challenging resistance patterns.

Mexico faces a significant burden of gram-negative infections attributed by 81.2% of Acinetobacter spp. and 57.9% of E. coli resistant to fluoroquinolones. of gram-negative bacilli. Market growth is shaped by increasing prevalence, growing awareness, and rising investment in R&D. However, limited healthcare infrastructure, high treatment costs, and antibiotic resistance restrain the market.

Mexico Gram Negative Infection Therapeutic Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Increasing Prevalence: Mexico reported high gram-negative bacilli which are antibiotic resistant. The growing number of cases necessitates the development and availability of effective therapeutics, thus driving the market.

Growing Awareness: Increased awareness among healthcare professionals and the public regarding the severity of gram-negative infections can drive demand for effective treatment options.

Growing Investment in R&D: Pharmaceutical companies are increasingly investing in research and development of novel therapeutics to address the challenge of MDR gram-negative infections. Introducing new drug classes like anti-lipopolysaccharide (LPS) agents and phage therapy holds promise for effectively treating gram-negative infections, thus driving the market.

Market Restraints

Limited Healthcare Infrastructure: Insufficient healthcare infrastructure in Mexico could hinder the effective distribution and administration of gram-negative infection therapeutics, affecting patient accessibility. This limited healthcare infrastructure makes it challenging for companies to expand their reach and provide effective treatments to patients, acting as a significant market restraint.

High Treatment Costs: The average cost of medical care per episode of nosocomial UTI (Urinary tract infection), an infection acquired in a hospital setting that gram-negative bacteria can cause, was $2062. The high costs of gram-negative infection therapeutics limit affordability and access for patients in Mexico, potentially restraining market growth.

Antibiotic Resistance: In Mexico, 81.2% of Acinetobacter spp. and 57.9% of E. coli resistant to fluoroquinolones. Increasing antibiotic resistance among gram-negative bacteria can complicate treatment outcomes and limit the effectiveness of existing therapeutics, posing a challenge for the market.

Regulatory Landscape and Reimbursement Scenario

The Federal Commission for Protection against Sanitary Risks (COFEPRIS) and the General Directorate of Medicines and New Technologies oversee the regulatory framework for gram-negative infection therapeutics in Mexico. COFEPRIS regulates drugs and medical devices, while the General Directorate explicitly handles the registration, evaluation, and approval of new medications. The reimbursement scenario in Mexico is complex, with a multi-tiered healthcare system consisting of the public (IMSS, ISSSTE) and private providers offering varying coverage for gram-negative infection therapeutics. The public system prioritizes cost-effectiveness and includes established, generic antibiotics on formularies, while coverage for newer or expensive therapies might be limited and require justification.

Private insurance plans typically offer broader coverage, with specific details depending on the individual's plan. Established generics with proven efficacy are likely reimbursed in both public and private systems, while novel therapeutics, particularly for MDR infections, might face limited coverage in the public sector unless supported by strong evidence of efficacy and cost-effectiveness. Patients may face co-payments or out-of-pocket costs depending on the chosen healthcare system and coverage plan, and healthcare providers must stay informed about formulary updates while potentially needing to justify the use of specific medications, especially newer or expensive options.

Competitive Landscape

Key Players

Here are some of the major key players in the Mexico Gram-Negative Infection Therapeutics Market:

Merck & Co., Inc.
Baxter
GlaxoSmithKline plc (GSK)
Takeda Pharmaceutical Company Limited
Pfizer Inc.
Sanofi-Aventis
Novartis
AbbVie Inc.
Bayer AG
Eli Lilly and Company

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Mexico Gram-Negative Infection Therapeutics Market Segmentation

By Drug Types

Antibiotics
Combination Therapies
Adjunctive Therapies

By Infection Types

Urinary Tract Infections (UTIs)
Pneumonia
Bloodstream Infections (Bacteraemia)
Wound/Surgical Site Infections
Gastrointestinal Infections
Meningitis
Hospital-Acquired Infections (HAIs)
Respiratory Tract Infections (RTIs)
Other Infections

By Route of Administration

Oral
Parenteral (injections, intravenous)
Topical

By Distribution Channel

Hospitals
Clinics
Ambulatory Surgical Centres
Home Healthcare
Long-term Care Facilities
Community Health Centres

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.